翻訳と辞書 |
Asunaprevir
|Section2= |Section6= |Section7= }} Asunaprevir (formerly BMS-650032, brand name in Japan and Russia Sunvepra) is an experimental drug candidate for the treatment of hepatitis C. It is undergoing development by Bristol-Myers Squibb and is currently in Phase III clinical trials.〔(【引用サイトリンク】 A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients )〕 Asunaprevir is an inhibitor of the hepatitis C virus enzyme serine protease NS3. Asunaprevir is being tested in combination with pegylated interferon and ribavirin, as well as in interferon-free regimens with other direct-acting antiviral agents including daclatasvir.〔(【引用サイトリンク】 Bristol-Myers' Daclatasvir, Asunaprevir Cured 77%: Study )〕〔(AASLD: Daclatasvir plus Asunaprevir Rapidly Suppresses HCV in Prior Null Responders ). Highleyman, L. HIVandHepatitis.com. 8 November 2011.〕 ==See also==
* Boceprevir * Telaprevir
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Asunaprevir」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|